Treatments in development
The development of new treatments is a long and difficult process. Fewer than one or two compounds in 10,000 tested actually make it through to being licensed treatments. A potential new medicine may be rejected at any point in the development process on safety, efficacy or quality grounds. On average it will take 10-15 years for a new compound to get from the test-tube into the medicine cabinet.
The following treatments are currently under development:
It is important to remember that not all these treatments will complete the development process and be licensed for general use (or be recommended by NICE or SMC).
Treatments in the pipeline for secondary progressive MS
| Treatment in development |
 |
| Masitinib |
 |
| Natalizumab |
 |
